52 completed, 24 unknown, 15 terminated, 13 recruiting. 125 Phase 3, 32 Phase 2.
Follow Cranial Nerve Diseases: new trials by email Literature Review of Cranial Nerve Diseases trials Research Report on Cranial Nerve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Trial of Botulinum Toxin A vs Strabismus Surgery for Esotropia >10 to ≤30PD Botulinum toxin A, bilateral medial rectus recession - Esotropia | Phase 3 | Not yet recruiting | Jaeb Center for Health Research | 244 | 2027-01-01 | 2026-04-06 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Cenegermin, Vehicle - Non-Arteritic Anterior Ischemic Optic Neuropathy | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 272 | 2026-07-01 | 2026-10-27 |
| A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy NIO752, Placebo - Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 300 | 2026-06-03 | 2026-10-15 |
| Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research Privosegtor, Methylprednisolone, Placebo - Optic Neuritis | Phase 3 | Recruiting | Oculis | 210 | 2026-05-28 | 2026-08-14 |
| A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 3 | Recruiting | Hoffmann-La Roche | 8 | 2026-05-06 | 2026-10-01 |
| Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder Eculizumab administration, High-dose corticosteroid pulse therapy, Plasma exchange (PE) - Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Recruiting | Tianjin Medical University General Hospital | 198 | 2026-01-01 | 2026-05-14 |
| Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis | Phase 3 | Recruiting | Beijing Tiantan Hospital | 364 | 2025-10-09 | 2026-10-26 |
| A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) Setmelanotide, Placebo - Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form | Phase 3 | Recruiting | Rhythm Pharmaceuticals, Inc. | 39 | 2025-09-23 | 2026-02-12 |
| Bifocal Spectacles vs. Single Vision Spectacles for Esotropia Greater at Near Bifocal Spectacles, Single Vision Lenses - Esotropia | Phase 3 | Withdrawn | Jaeb Center for Health Research | 2025-09-01 | 2025-05-31 | |
| Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD Slow-tapering glucocorticoids + Inebilizumab, Rapid-tapering glucocorticoids + Inebilizumab - Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Not yet recruiting | Tianjin Medical University General Hospital | 170 | 2025-09-01 | 2025-08-20 |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX - Optic Neuritis, Myelitis | Phase 3 | Recruiting | Mayo Clinic | 382 | 2025-07-11 | 2026-09-24 |
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study] HAL lenses for children with strabismus, SVL for children with strabismus - Myopia, Strabismus | Phase 3 | Not yet recruiting | Singapore National Eye Centre | 40 | 2025-06-01 | 2025-03-07 |
| Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD eculizumab - NMOSD, Neuromyelitis Optica Spectrum Disorders | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 21 | 2025-01-16 | 2025-12-19 |
| A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation rAAV2-ND4, Sham (No Treatment) - Leber Hereditary Optic Neuropathy (LHON) | Phase 3 | Active not recruiting | Wuhan Neurophth Biotechnology Limited Company | 95 | 2024-09-19 | 2026-02-12 |
| A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) B001, Placebo - Neuromyelitis Optica Spectrum Disorders | Phase 2 / Phase 3 | Recruiting | Shanghai Jiaolian Drug Research and Development Co., Ltd | 132 | 2024-07-17 | 2026-05-05 |
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Azathioprine in MOGAD Azathioprine, Placebo - Central Nervous System Inflammation, MOG-IgG Associated Disease | Phase 3 | Recruiting | Hospices Civils de Lyon | 126 | 2023-12-12 | 2025-02-04 |
| Safety and Efficacy of Botulinum Toxin A in Patients With Trigeminal Neuralgia Botulinum toxin A, Isotonic saline - Trigeminal Neuralgia | Phase 3 | Unknown | Henrik Schytz | 80 | 2023-11-01 | 2024-03-18 |
Showing 20 of 125. Sign in to see all of them.
Neuromyelitis Optica (25) · Optic Neuritis (18) · Optic Atrophy, Hereditary, Leber (11) · Multiple Sclerosis (10) · Strabismus (9) · Supranuclear Palsy, Progressive (9) · Trigeminal Neuralgia (9) · Esthesioneuroblastoma, Olfactory (8) · Demyelinating Diseases (7) · Head and Neck Neoplasms (7) · Myelitis, Transverse (7) · Squamous Cell Carcinoma of Head and Neck (7) · Eye Diseases (6) · Eye Diseases, Hereditary (6) · Ocular Motility Disorders (6)
Nervous System Diseases (121) · Eye Diseases (90) · Optic Nerve Diseases (60) · Pathological Conditions, Signs and Symptoms (44) · Immune System Diseases (38) · Autoimmune Diseases (36) · Signs and Symptoms (36) · Autoimmune Diseases of the Nervous System (35) · Demyelinating Autoimmune Diseases, CNS (35) · Neurologic Manifestations (31) · Central Nervous System Diseases (30) · Demyelinating Diseases (28) · Neurodegenerative Diseases (26) · Ocular Motility Disorders (25)
Botulinum Toxins, Type A (5) · Methylprednisolone (5) · salicylhydroxamic acid (5) · Adrenal Cortex Hormones (4) · Azathioprine (4) · eculizumab (4) · satralizumab (4) · Dexamethasone (3) · Rituximab (3) · ravulizumab (3) · Cyclophosphamide (2) · Ginkgo Extract (2) · Immunoglobulins, Intravenous (2) · Methylprednisolone Acetate (2) · Methylprednisolone Hemisuccinate (2)
National Eye Institute (NEI) (8) · Alexion Pharmaceuticals, Inc. (7) · GenSight Biologics (4) · Hoffmann-La Roche (4) · Tianjin Medical University General Hospital (4) · Alliance for Clinical Trials in Oncology (2) · Asociación para Evitar la Ceguera en México (2) · Assistance Publique - Hôpitaux de Paris (2) · Biogen (2) · Chonbuk National University (2) · Jaeb Center for Health Research (2) · Novartis Pharmaceuticals (2) · Pennsylvania College of Optometry (2) · Wuhan Neurophth Biotechnology Limited Company (2) · ACADIA Pharmaceuticals Inc. (1)
United States (61) · United Kingdom (24) · France (22) · Italy (22) · Germany (21) · China (17) · Spain (16) · South Korea (14) · Canada (13) · Australia (12) · Japan (10) · Poland (8) · Turkey (Türkiye) (8) · Taiwan (7) · Denmark (6)
Mitchell Scheiman, OD (4) · Nancy Newman, MD (2) · Adam Boxer, M.D., PhD. (1) · Adam Sivitz, MD (1) · Alan B Scott, MD (1) · Arnaldo Rivera, MD (1) · Arnold M. Markoe, MD, ScD (1) · Axel Petzold, Dr. (1) · Ayman Tourbah, MD, PhD (1) · Bin Li, MD (1) · Bin Li, PhD,MD (1)
PMID 33263359, PMID 36449262, PMID 34108929, PMID 40743487, PMID 33676197, PMID 34498507, PMID 36007339, PMID 36724181, PMID 40288333, PMID 1463007, PMID 15642806, PMID 16044063, PMID 16170124, PMID 1674640, PMID 18441370, PMID 18441371, PMID 18774912, PMID 18852411, PMID 19029129, PMID 19151384, PMID 1928099, PMID 19668097, PMID 19741558, PMID 19771175, PMID 20126486, PMID 20406930, PMID 20543758, PMID 21386111, PMID 21621166, PMID 21829612, PMID 21921071, PMID 22170885, PMID 22480131, PMID 22612072, PMID 22644094, PMID 22665535, PMID 22922781, PMID 23063736, PMID 24396955, PMID 24733799, PMID 24756302, PMID 24756514, PMID 24781936, PMID 24873720, PMID 25063544, PMID 25370510, PMID 25370513, PMID 25950380, PMID 26009577, PMID 26024112
2017 (4), 2014 (3), 2015 (3), 2016 (3), 2019 (3), 2008 (1), 2018 (1), 2023 (1), K23NS050485 (1), P30CA008748 (1), R01CA107080 (1), R21CA098792 (1), R21EY013164 (1), U10CA037404 (1), U10CA081920 (1)